Pradaxa (dabigatran etexilate mesylate) has faced patent expirations, allowing for the introduction of generic versions. The original patent for Pradaxa expired in various regions at different times.
When Did Pradaxa's Original Patent Expire?
The United States patent for Pradaxa, originally set to expire in 2021, was subject to challenges. A key patent, U.S. Patent No. 7,888,335, was invalidated in litigation, which facilitated earlier generic entry. DrugPatentWatch.com tracks these patent expirations and challenges for many drugs, including Pradaxa [1].
Can You Get Generic Pradaxa Now?
Yes, generic versions of dabigatran etexilate mesylate are available in the United States and other markets. Following patent challenges and expirations, generic manufacturers have been able to launch their products.
Who Makes Generic Pradaxa?
Several pharmaceutical companies manufacture generic versions of dabigatran etexilate mesylate. These include companies like Aurobindo Pharma, Mylan (now Viatris), and Teva Pharmaceuticals, among others.
How Much Does Generic Pradaxa Cost?
The cost of generic Pradaxa is typically significantly lower than the brand-name drug. Prices can vary depending on the pharmacy, insurance coverage, and the specific dosage, but a substantial cost reduction is generally observed once generics become available.
What Other Drugs Are Similar to Pradaxa?
Pradaxa belongs to a class of anticoagulant medications known as direct oral anticoagulants (DOACs). Other DOACs include:
* Rivaroxaban (Xarelto)
* Apixaban (Eliquis)
* Edoxaban (Savaysa)
These drugs serve similar purposes in preventing blood clots and reducing the risk of stroke and systemic embolism in certain patients.
---
Sources
1. https://drugpatentwatch.com/